Treatment Action Group’s independent, peer-reviewed analysis found public investment in the development of bedaquiline was up to five times that of Johnson and Johnson. This finding appears in the new PLOS ONE article, “Public Investments in the Clinical Development of Bedaquiline.”
Treatment Action Group (TAG) strongly condemns alleged bullying, harassment, and racism directed toward staff and contractors of the Stop TB Partnership, as reported by The New York Times. As a long-term and current grantee of the Stop TB Partnership, we stand in solidarity with current and former staff and contractors whom this harassment and racism has affected.
As the COVID-19 pandemic continues to radically shift the global health landscape and alter government/donor commitments, TAG has released this timely brief to explore the impact of COVID-19 on TB research and development (R&D), and how tools, concepts, capacity, and…
In these two webinars, Treatment Action Group (TAG) launched the two latest additions to our series of materials designed for community leaders, An Activist’s Guide to Treatment for Drug-Resistant Tuberculosis and An Activist’s Guide to Tuberculosis Diagnostic Tools.
Treatment Action Group, the New York City-based research, policy, and advocacy organization, deplores the August 4, 2020 departure of New York’s Department of Health Commissioner, Dr. Oxiris Barbot, MD.
TAG and our French partners OTMeds (Observatoire de la transparence dans les politiques du médicaments) sent a letter to Sanofi CEO Paul Hudson calling on the company to reverse its efforts to patent two obvious combinations of two critical drugs to prevent tuberculosis: rifapentine and isoniazid.
Our publication, An Activist’s Guide to Tuberculosis Diagnostic Tools, details the latest WHO recommendations, the array of available TB diagnostic tools, and how these tools should be optimally used in country programs, including to support TB screening and diagnosis among special populations such as children, people with extrapulmonary TB, and people living with HIV/AIDS (PLWHA).
Treatment Action Group (TAG) honors the titanic historic legacy and mourns the recent death of the Honorable John Lewis, U.S. Representative from the 5th Congressional district in Georgia and legendary civil rights leader.
AVAC, Health GAP and the Treatment Action Group (TAG) strongly condemn the Trump Administration’s withdrawal from the World Health Organization (WHO).
Treatment Action Group welcomes the Global Drug Facility / Stop TB Partnership's negotiation of what amounts to a 32% savings on bedaquiline, the backbone of improved, all-oral regimens for treating drug-resistant TB.